These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancer. Konecny GE; Winterhoff B; Kolarova T; Qi J; Manivong K; Dering J; Yang G; Chalukya M; Wang HJ; Anderson L; Kalli KR; Finn RS; Ginther C; Jones S; Velculescu VE; Riehle D; Cliby WA; Randolph S; Koehler M; Hartmann LC; Slamon DJ Clin Cancer Res; 2011 Mar; 17(6):1591-602. PubMed ID: 21278246 [TBL] [Abstract][Full Text] [Related]
3. Proliferative suppression by CDK4/6 inhibition: complex function of the retinoblastoma pathway in liver tissue and hepatoma cells. Rivadeneira DB; Mayhew CN; Thangavel C; Sotillo E; Reed CA; Graña X; Knudsen ES Gastroenterology; 2010 May; 138(5):1920-30. PubMed ID: 20100483 [TBL] [Abstract][Full Text] [Related]
4. Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo. Tao Z; Le Blanc JM; Wang C; Zhan T; Zhuang H; Wang P; Yuan Z; Lu B Clin Cancer Res; 2016 Jan; 22(1):122-33. PubMed ID: 26728409 [TBL] [Abstract][Full Text] [Related]
5. Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy. Xu L; Cheng Z; Cui C; Wu X; Yu H; Guo J; Kong Y J Transl Med; 2019 Jul; 17(1):245. PubMed ID: 31358010 [TBL] [Abstract][Full Text] [Related]
6. CDKN2A/p16 Loss Implicates CDK4 as a Therapeutic Target in Imatinib-Resistant Dermatofibrosarcoma Protuberans. Eilers G; Czaplinski JT; Mayeda M; Bahri N; Tao D; Zhu M; Hornick JL; Lindeman NI; Sicinska E; Wagner AJ; Fletcher JA; Mariño-Enriquez A Mol Cancer Ther; 2015 Jun; 14(6):1346-53. PubMed ID: 25852058 [TBL] [Abstract][Full Text] [Related]
7. CDK4, CDK6, cyclin D1, p16(INK4a) and EGFR expression in glioblastoma with a primitive neuronal component. Xu G; Li JY J Neurooncol; 2018 Feb; 136(3):445-452. PubMed ID: 29150788 [TBL] [Abstract][Full Text] [Related]
8. Predictors of ribociclib-mediated antitumour effects in native and sorafenib-resistant human hepatocellular carcinoma cells. Reiter FP; Denk G; Ziesch A; Ofner A; Wimmer R; Hohenester S; Schiergens TS; Spampatti M; Ye L; Itzel T; Munker S; Teufel A; Gerbes AL; Mayerle J; De Toni EN Cell Oncol (Dordr); 2019 Oct; 42(5):705-715. PubMed ID: 31250364 [TBL] [Abstract][Full Text] [Related]
10. Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy. Roberts PJ; Bisi JE; Strum JC; Combest AJ; Darr DB; Usary JE; Zamboni WC; Wong KK; Perou CM; Sharpless NE J Natl Cancer Inst; 2012 Mar; 104(6):476-87. PubMed ID: 22302033 [TBL] [Abstract][Full Text] [Related]
11. The CDK4/6 inhibitor PD0332991 reverses epithelial dysplasia associated with abnormal activation of the cyclin-CDK-Rb pathway. Cabrera MC; Díaz-Cruz ES; Kallakury BV; Pishvaian MJ; Grubbs CJ; Muccio DD; Furth PA Cancer Prev Res (Phila); 2012 Jun; 5(6):810-21. PubMed ID: 22508966 [TBL] [Abstract][Full Text] [Related]
12. Specific Antileukemic Activity of PD0332991, a CDK4/6 Inhibitor, against Philadelphia Chromosome-Positive Lymphoid Leukemia. Nemoto A; Saida S; Kato I; Kikuchi J; Furukawa Y; Maeda Y; Akahane K; Honna-Oshiro H; Goi K; Kagami K; Kimura S; Sato Y; Okabe S; Niwa A; Watanabe K; Nakahata T; Heike T; Sugita K; Inukai T Mol Cancer Ther; 2016 Jan; 15(1):94-105. PubMed ID: 26637365 [TBL] [Abstract][Full Text] [Related]
13. SPH3643: A novel cyclin-dependent kinase 4/6 inhibitor with good anticancer efficacy and strong blood-brain barrier permeability. Liao X; Hong Y; Mao Y; Chen N; Wang Q; Wang Z; Zhang L; Wang L; Shi C; Shi W; Ge H; Li A; Li X; Xia G; Liu Y Cancer Sci; 2020 May; 111(5):1761-1773. PubMed ID: 32103527 [TBL] [Abstract][Full Text] [Related]
14. Expression of p16Ink4a compensates for p18Ink4c loss in cyclin-dependent kinase 4/6-dependent tumors and tissues. Ramsey MR; Krishnamurthy J; Pei XH; Torrice C; Lin W; Carrasco DR; Ligon KL; Xiong Y; Sharpless NE Cancer Res; 2007 May; 67(10):4732-41. PubMed ID: 17510401 [TBL] [Abstract][Full Text] [Related]
15. Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA. Perez M; Muñoz-Galván S; Jiménez-García MP; Marín JJ; Carnero A Oncotarget; 2015 Dec; 6(38):40557-74. PubMed ID: 26528855 [TBL] [Abstract][Full Text] [Related]
16. Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM. Wiedemeyer WR; Dunn IF; Quayle SN; Zhang J; Chheda MG; Dunn GP; Zhuang L; Rosenbluh J; Chen S; Xiao Y; Shapiro GI; Hahn WC; Chin L Proc Natl Acad Sci U S A; 2010 Jun; 107(25):11501-6. PubMed ID: 20534551 [TBL] [Abstract][Full Text] [Related]
17. PD-0332991, a CDK4/6 inhibitor, significantly prolongs survival in a genetically engineered mouse model of brainstem glioma. Barton KL; Misuraca K; Cordero F; Dobrikova E; Min HD; Gromeier M; Kirsch DG; Becher OJ PLoS One; 2013; 8(10):e77639. PubMed ID: 24098593 [TBL] [Abstract][Full Text] [Related]
18. Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Michaud K; Solomon DA; Oermann E; Kim JS; Zhong WZ; Prados MD; Ozawa T; James CD; Waldman T Cancer Res; 2010 Apr; 70(8):3228-38. PubMed ID: 20354191 [TBL] [Abstract][Full Text] [Related]
19. Loss of CDKN2A expression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines. Young RJ; Waldeck K; Martin C; Foo JH; Cameron DP; Kirby L; Do H; Mitchell C; Cullinane C; Liu W; Fox SB; Dutton-Regester K; Hayward NK; Jene N; Dobrovic A; Pearson RB; Christensen JG; Randolph S; McArthur GA; Sheppard KE Pigment Cell Melanoma Res; 2014 Jul; 27(4):590-600. PubMed ID: 24495407 [TBL] [Abstract][Full Text] [Related]
20. Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients. Vlenterie M; Hillebrandt-Roeffen MH; Schaars EW; Flucke UE; Fleuren ED; Navis AC; Leenders WP; Versleijen-Jonkers YM; van der Graaf WT Ann Surg Oncol; 2016 Sep; 23(9):2745-52. PubMed ID: 27334220 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]